Cipla Launches Generic Saxenda in US as GLP-1 Competition Intensifies
Cipla has launched a generic Saxenda (liraglutide) in the U.S., crediting Orbicular’s FDA approval, a move with supply and sourcing implications for the GLP-1 peptide market.
Cipla has launched a generic Saxenda (liraglutide) in the U.S., crediting Orbicular’s FDA approval, a move with supply and sourcing implications for the GLP-1 peptide market.